Skip to main content

Table 1 Demographics and clinical characteristics

From: Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis

 

Nonactive disease

Active disease

Total

Patients

14

60

74

Age (years)

37.5 (26.2 to 37.5)

34.0 (28.0 to 40.0)

35.0 (27.5 to 42.0)

Female/male

11/3

52/8

63/11

Race: African American, Hispanic, White

7, 7, 0

26, 27, 7

33, 34, 7

SLEDAI

2 (0 to 5.25)

10 (4 to 17)

10 (4 to 16)

Renal SLEDAI

0

8 (4 to 8)

4 (4 to 8)

Renal pathology

   

World Health Organization classification

  

   II

4

8

12

   III

1

16

17

   IV

3

25

28

   V

6

7

13

   Unknown

0

3

3

Protein:creatinine ratio

0.190 ± 0.040

1.536 ± 0.229*

1.278 ± 0.195

Serum creatinine

1.422 ± 0.403

1.738 ± 0.191

1.677 ± 0.172

Positive anti-dsDNA (total tested)

4 (11)

30 (50)

34 (61)

Hypocomplementemia (total tested)

9 (11)

35 (46)

44 (57)

Current medications

   

   Prednisone

10

47

57

   Mycophenolic acid

5

24

29

   Cyclophosphamide

0

3

3

   Azathioprine

2

3

5

   Methotrexate

1

1

2

   Cyclosporin A

0

1

1

   Angiotensin blocking agents

9

32

41

   Hydrochloroquine

7

26

33

  1. Data presented as n, median (interquartile range) or mean ± standard error. Nonactive disease, renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) = 0; active disease, renal SLEDAI > 0. dsDNA, double-stranded DNA. *P < 0.01, active versus nonactive.